(2R,3S,4R,5S,6S)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Term ID

CHEBI:152710

Synonyms

6-deoxy-beta-L-galacto-hexopyranosyl-(1->2)-[beta-D-galacto-hexopyranosyl-(1->3)]-beta-D-gluco-hexopyranose
Fuc(b1-2)[Gal(b1-3)]b-Glc
WURCS=2.0/3,3,2/[a2122h-1b_1-5][a1221m-1b_1-5][a2112h-1b_1-5]/1-2-3/a2-b1_a3-c1

Definition

References

GlyGen:G63611ZF
GlyTouCan:G63611ZF

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3S,4R,5S,6S)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype where environments contain (2R,3S,4R,5S,6S)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype modified by environments containing (2R,3S,4R,5S,6S)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Phenotype affecting (2R,3S,4R,5S,6S)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

Human Disease Model